A study evaluating safety and efficacy of treatment with once daily ledipasvir/sofosbuvir for 12 weeks in genotype 1 HCV infected patients with severe renal impairment.
Phase of Trial: Phase IV
Latest Information Update: 13 Nov 2017
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 13 Nov 2017 New trial record
- 24 Oct 2017 Complete SVR12, PK, and echocardiogram results will be presented.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases